



Orion produces and exports active pharmaceutical ingredients and finished products to the global market

ORION has 6 manufacturing plants in FINLAND, sales offices in 31 countries

ORION exports its own products to more than 100 countries worldwide

METHOTREXATE

- global market share more than 30%

DAROLUTAMIDE

1 in 7 cancer patients has prostate cancer. 1.2 million new patients per year

ENTACAPONE

- in more than 50% of the world's Parkinson's drugs



ORION

Orion today







Net sales 1,041 MEUR



Operating profit **243** MEUR



Personnel 3,355



R&D investments 118 MEUR




6 production sites in Finland



Own sales unit in **26** European and **5** Asia-Pacific countries

Established in 1917

Sales by business



■ Proprietary Products


Specialty Products

Animal Health

■ Fermion & CM*

*) Contract manufacturing

Sales by market area



■ Finland

Scandinavia

Other Europe

■ North America

ROW

ORION

2025 Growth target - In-licensing as a growth driver



Headwinds

Organic growth in all units - including new in-licensed products

Geographical expansion

In-licensing & M&As are options in all units

Darolutamide ARANOTE*

Easyhaler® tiotropium*

Possible changes in regulation (pricing etc.)








COMTan

Comtess

Generics pricing pressure



Key clinical development pipeline

Project/compound	Indication	Phase I	Phase II	Phase III Registration
ARASENS / darolutamide ¹	Prostate cancer (mHSPC)	Phase I	Phase II	Phase III Registration
ARANOTE / darolutamide ¹	Prostate cancer (mHSPC)	Phase I	Phase II	Phase III
ODM-208 ²	Prostate cancer (mCRPC)	Phase I	Phase II	Phase completed
ODM-105 / tasipimidine	Treatment of psychiatric disorders	Phase I		Phase ongoing
ODM-111 (NaV 1.8 blocker)	Pain	Phase I		
Easyhaler® tiotropium	COPD	Bio	pequivalence stu	udy

Oncology

Pain / neurology

Updates vs. Q2 2022:


- Development of Easyhaler® tiotropium terminated
- ODM-105 Phase I ready
- ODM-111 entered Phase I



¹ In collaboration with Bayer

² In collaboration with MSD

CAR T-soluterapia-tutkimushanke yhteistyössä Suomen Punaisen Ristin Veripalvelun kanssa









Kiitos.....

